Business Context and Reporting Period
This Form 8-K, filed on February 12, 2007, by Cyclacel Pharmaceuticals, Inc. (formerly Bio Green Med Solution, Inc.), serves to provide historical financial data and management discussion in connection with a universal shelf Registration Statement on Form S-3. The financial data presented covers the period from the company's inception in August 1996 through December 31, 2005. Cyclacel is a development-stage biopharmaceutical company focused on cell cycle biology and the development of orally available anticancer agents. On March 27, 2006, Cyclacel was acquired by Xcyte Therapies, Inc. and became a wholly-owned subsidiary.
Key Financial Metrics
The company has not generated significant product revenue and has incurred net losses since inception. As of December 31, 2005, the accumulated deficit was approximately $109.0 million.
| Metric | Year Ended Dec 31, 2005 | Year Ended Dec 31, 2004 | 9 Months Ended Dec 31, 2003 |
|---|---|---|---|
| Total Revenue | $356,000 | $925,000 | $512,000 |
| Net Loss | $(18,048,000) | $(22,742,000) | $(14,977,000) |
| Net Loss to Ordinary Shareholders | $(29,924,000) | $(33,795,000) | $(19,402,000) |
| Research & Development Expenses | $(15,841,000) | $(20,332,000) | $(13,258,000) |
| Cash and Cash Equivalents | $3,117,000 | $7,766,000 | $4,335,000 |
| Short-term Investments | $10,690,000 | $15,152,000 | $29,345,000 |
| Working Capital | $2,152,000 | $20,909,000 | $34,383,000 |
| Long-term Debt | $(78,000) | $(368,000) | $(495,000) |
Revenue sources consist primarily of government grants and collaboration/research revenue. The company has received $103.5 million in equity proceeds since inception, along with $3.3 million in government grants and $10.2 million in R&D tax credits.
Material Changes vs. Prior Period
- Revenue: Total revenue decreased by $0.5 million in 2005 compared to 2004, primarily due to the completion of program work associated with government grants.
- R&D Expenses: Decreased by $4.5 million in 2005 compared to 2004. This reduction reflected the completion of recruitment for seliciclib Phase IIa trials and a strategic decision to reduce expenses and focus resources on oncology development.
- General and Administrative Expenses: Increased by $1.7 million in 2005 compared to 2004, driven by higher intellectual property maintenance fees and costs related to financing activities.
- Liquidity: Cash and short-term investments declined from $22.9 million at year-end 2004 to $13.8 million at year-end 2005 due to operating losses and capital expenditures.
- Corporate Structure: The company was acquired by Xcyte Therapies, Inc. in March 2006, resolving previous liquidity concerns regarding operations beyond August 2006.
Guidance, Outlook, and Risks
Outlook and Funding: Following the acquisition by Xcyte and a subsequent private placement of equity raising $45.3 million in April 2006, management believes the company has sufficient funding to meet ongoing working capital requirements. The company expects to incur substantial and continued losses for the next several years as it advances drug candidates, seeks regulatory approvals, and expands R&D.
Drug Development Pipeline:
- Seliciclib: Lead candidate (CDK inhibitor). Completed recruitment in four Phase II trials in Europe; final data expected in 2007. Currently in a Phase IIb trial in the U.S. for non-small cell lung cancer.
- Sapacitabine: Completed Phase I studies for refractory solid tumors and lymphomas; currently in Phase I for certain leukemias.
- CYC116: Aurora kinase and VEGFR2 inhibitor. IND filed with the FDA in December 2006; clinical development expected to commence in 2007.
Risks and Contingencies:
- Development Uncertainty: There is no guarantee that drug candidates will successfully complete clinical trials or receive regulatory approval. Timelines and costs are highly uncertain.
- Market Risk: Exposure is limited to interest rate sensitivity on short-term investments; no foreign currency or derivative instruments are held.
- Contractual Obligations: The company has milestone payment obligations totaling $23.4 million payable to partners upon achievement of specific milestones, though annual payments do not exceed $0.1 million.
Investor Verification Checklist
- Verify the status and final data release of the seliciclib Phase II trials expected in 2007.
- Confirm the integration of Cyclacel's operations and funding status post-acquisition by Xcyte Therapies, Inc.
- Review the terms of the $45.3 million private placement completed in April 2006, including warrant exercise conditions.
- Assess the timeline and cost estimates for advancing CYC116 into clinical development in 2007.
- Monitor the company's ability to meet milestone payment obligations to partners without requiring additional dilutive financing.